Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$2.05 +1.5%	$2.17	$1.88 ▼ $7.67	$25.21M	0.66	81,683 shs	4,261 shs
ELUT Elutia	$2.33 +7.4%	$2.75	$1.87 ▼ $5.24	$94.92M	0.96	48,933 shs	21,578 shs
GNLX Genelux	$2.88 -7.4%	$3.32	$1.60 ▼ $5.89	$99.66M	-0.36	210,168 shs	95,457 shs
ZURA Zura Bio	$1.37 -4.9%	$1.27	$0.97 ▼ $6.35	$93.67M	0.08	386,360 shs	163,088 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	+1.49%	+1.49%	-2.84%	-23.08%	-15.98%
ELUT Elutia	+7.37%	+0.43%	-10.38%	-25.56%	-19.38%
GNLX Genelux	-7.40%	+9.51%	-10.00%	-27.27%	-16.52%
ZURA Zura Bio	-4.86%	+11.38%	+2.62%	-20.35%	-58.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	3.8116 of 5 stars	3.5	3.0	4.3	2.2	1.7	0.0
ELUT Elutia	3.2794 of 5 stars	3.5	3.0	0.0	2.1	5.0	0.6
GNLX Genelux	1.8772 of 5 stars	3.6	2.0	0.0	3.8	0.0	0.0
ZURA Zura Bio	2.9081 of 5 stars	3.6	3.0	0.0	2.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	95.12% Upside
ELUT Elutia	3.00	Buy	$9.00	286.27% Upside
GNLX Genelux	3.20	Buy	$18.25	533.68% Upside
ZURA Zura Bio	3.13	Buy	$14.67	970.56% Upside

Current Analyst Ratings Breakdown

Latest CASI, ELUT, ZURA, and GNLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/31/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
3/25/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/7/2025	ELUT Elutia	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $8.00

(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$28.54M	0.88	N/A	N/A	$1.81 per share	1.13
ELUT Elutia	$24.38M	3.89	N/A	N/A	($1.66) per share	-1.40
GNLX Genelux	$8K	12,457.44	N/A	N/A	$0.73 per share	3.95
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$26.94M	-$2.57	N/A	∞	N/A	-143.18%	-181.52%	-45.72%	5/13/2025 (Estimated)
ELUT Elutia	-$37.66M	-$2.47	N/A	N/A	N/A	-218.72%	N/A	-142.61%	5/8/2025 (Estimated)
GNLX Genelux	-$28.30M	-$0.96	N/A	N/A	N/A	N/A	-105.05%	-80.16%	5/8/2025 (Estimated)
ZURA Zura Bio	-$69.24M	-$0.53	N/A	N/A	N/A	N/A	-37.36%	-29.81%	5/8/2025 (Estimated)

Latest CASI, ELUT, ZURA, and GNLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	N/A	CASI CASI Pharmaceuticals	-$0.61	N/A	N/A	N/A	$7.39 million	N/A
5/8/2025	N/A	GNLX Genelux	-$0.24	N/A	N/A	N/A	N/A	N/A
5/8/2025	N/A	ZURA Zura Bio	-$0.17	N/A	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	CASI CASI Pharmaceuticals	-$0.60	-$0.79	-$0.19	-$0.79	$7.39 million	$13.36 million
3/28/2025	Q4 2024	GNLX Genelux	-$0.17	-$0.26	-$0.09	-$0.26	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	1.38	3.20	2.32
ELUT Elutia	N/A	0.94	0.85
GNLX Genelux	N/A	6.47	6.47
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
ELUT Elutia	74.03%
GNLX Genelux	37.33%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
ELUT Elutia	27.60%
GNLX Genelux	9.30%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	12.20 million	Optionable
ELUT Elutia	180	40.74 million	20.46 million	Not Optionable
GNLX Genelux	10	34.60 million	31.33 million	Not Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

CASI, ELUT, ZURA, and GNLX Headlines

Recent News About These Companies

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24 at 5:19 PM | finance.yahoo.com

JPMorgan Chase & Co. Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)

April 20, 2025 | marketbeat.com

Head-To-Head Comparison: Zura Bio (ZURA) & The Competition

April 19, 2025 | americanbankingnews.com

Comparing Zura Bio (ZURA) and Its Rivals

April 17, 2025 | americanbankingnews.com

ADAR1 Capital Management LLC Cuts Stake in Zura Bio Limited (NASDAQ:ZURA)

April 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings

April 8, 2025 | marketbeat.com

HC Wainwright Cuts Zura Bio (NASDAQ:ZURA) Price Target to $3.00

April 5, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

April 5, 2025 | marketbeat.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Analysts Set Expectations for Zura Bio FY2025 Earnings

March 29, 2025 | marketbeat.com

Q1 Earnings Forecast for Zura Bio Issued By Leerink Partnrs

March 29, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Releases Quarterly Earnings Results

March 28, 2025 | marketbeat.com

Zura Bio's (ZURA) Buy Rating Reaffirmed at Guggenheim

March 27, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Price Target Cut to $10.00 by Analysts at Chardan Capital

March 27, 2025 | marketbeat.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
Top 3 S&P 500 Winners in a Losing Market
By Ryan Hasson | April 9, 2025
View Top 3 S&P 500 Winners in a Losing Market

CASI, ELUT, ZURA, and GNLX Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$2.02 +0.01 (+0.25%)

As of 04/25/2025 04:00 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Elutia NASDAQ:ELUT

$2.34 +0.17 (+7.65%)

As of 04/25/2025 04:00 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Genelux NASDAQ:GNLX

$2.88 -0.23 (-7.40%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$2.95 +0.07 (+2.43%)

As of 04/25/2025 07:47 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Zura Bio NASDAQ:ZURA

$1.37 -0.07 (-4.86%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.00 (+0.36%)

As of 04/25/2025 05:28 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time